Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway

Ya-Jia Xie,Wei-Na Gao,Qi-Biao Wu,Xiao-Jun Yao,Ze-Bo Jiang,Yu-Wei Wang,Wen-Jun Wang,Wei Li,Shahid Hussain,Liang Liu,Elaine Lai-Han Leung,Xing-Xing Fan

DOI: https://doi.org/10.1016/j.phrs.2020.104934

IF: 10.334

2020-09-01

Pharmacological Research

Abstract:<p>Tyrosine kinase inhibitors (TKIs) have been widely used for the clinical treatment of patients with non-small cell lung cancer (NSCLC) harboring mutations in the EGFR. Unfortunately, due to the secondary mutation in EGFR, eventual drug-resistance is inevitable. Therefore, to overcome the resistance, new agent is urgently required. Chelidonine, extracted from the roots of <em>chelidonium majus</em>, was proved to effectively suppress the growth of NSCLC cells with EGFR double mutation. Proteomics analysis indicated that mitochondrial respiratory chain was significantly inhibited by chelidonine, and inhibitor of AMPK effectively blocked the apoptosis induced by chelidonine. Molecular dynamics simulations indicated that chelidonine could directly bind to EGFR and showed a much higher binding affinity to EGFR^L858R/T790M than EGFR^WT, which demonstrated that chelidonine could selectively inhibit the phosphorylation of EGFR in cells with EGFR double-mutantion. <em>In vivo</em> study revealed that chelidonine has a similar inhibitory effect like second generation TKI Afatinib. In conclusion, targeting EGFR and inhibition of mitochondrial function is a promising anti-cancer therapeutic strategy for inhibiting NSCLC with EGFR mutation and TKI resistance.</p>

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem this paper attempts to address is overcoming resistance to Gefitinib in non-small cell lung cancer (NSCLC). Specifically, the researchers have identified a compound called Chelidonine, which can specifically inhibit the growth of Gefitinib-resistant NSCLC cells with EGFR double mutations (L858R/T790M). Through a series of in vitro and in vivo experiments, the researchers explored the mechanism of action of Chelidonine and found that it inhibits cell growth and induces apoptosis through the EGFR-AMPK signaling pathway.

The main research contents include:
1. **Selective Inhibition**: Chelidonine exhibits significant selective inhibition on NSCLC cells with EGFR double mutations (such as H1975 cells) while showing lower toxicity to normal lung fibroblasts and epithelial cells.
2. **Cell Cycle Arrest and Apoptosis**: After Chelidonine treatment, cells are arrested in the G2/M phase and apoptosis is induced, as evidenced by the activation of PARP and Caspase-3 and the increase of Bax.
3. **Mitochondrial Dysfunction**: Chelidonine treatment leads to mitochondrial dysfunction, characterized by reduced oxygen consumption rate, decreased mitochondrial membrane potential, and increased ROS levels.
4. **AMPK Signaling Pathway**: Chelidonine promotes apoptosis by activating the AMPK signaling pathway and inhibiting the phosphorylation of mTOR and its downstream proteins.
5. **Direct Target**: Molecular docking studies indicate that Chelidonine has a high binding affinity to the EGFR L858R/T790M mutant, thereby selectively inhibiting its phosphorylation.
6. **In Vivo Experiments**: In a nude mouse xenograft model, Chelidonine significantly inhibits tumor growth without noticeable weight loss.

In summary, this study provides a potential therapeutic strategy to overcome EGFR-TKI resistance by targeting the EGFR and AMPK signaling pathways with Chelidonine to inhibit the growth of resistant NSCLC cells.